Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)

PHASE4TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Plaque Psoriasis

Interventions

DRUG

Calcipotriene/betamethasone

One application to affected areas, once a day for two weeks. The PI may choose to extend treatment until Week 4 if necessary.

Trial Locations (1)

DermResearch, PLLC, Louisville